NCT07232602 2026-03-16
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT07287995 2026-03-16
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT06434350 2026-03-02
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07421700 2026-02-19
A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Not yet recruiting
NCT06483334 2026-02-18
MK-3475-04C
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03288545 2025-11-10
EV-103
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06394570 2025-09-15
STAR-EV
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT07157956 2025-09-05
CVL006-T1002
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting